On Monday, Intellia Therapeutics Inc (NASDAQ: NTLA) opened lower -3.18% from the last session, before settling in for the closing price of $9.44. Price fluctuations for NTLA have ranged from $5.90 to $28.25 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -20.04%. Company’s average yearly earnings per share was noted 23.83% at the time writing. With a float of $110.12 million, this company’s outstanding shares have now reached $115.79 million.
Intellia Therapeutics Inc (NTLA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Intellia Therapeutics Inc is 4.93%, while institutional ownership is 86.29%. The most recent insider transaction that took place on Dec 11 ’25, was worth 836,384. In this transaction President and CEO of this company sold 88,146 shares at a rate of $9.49, taking the stock ownership to the 1,038,928 shares. Before that another transaction happened on Dec 11 ’25, when Company’s Officer proposed sale 88,146 for $9.33, making the entire transaction worth $822,402.
Intellia Therapeutics Inc (NTLA) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -1.27 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.32) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.78% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Check out the current performance indicators for Intellia Therapeutics Inc (NTLA). In the past quarter, the stock posted a quick ratio of 6.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.27, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -3.62 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
The latest stats from [Intellia Therapeutics Inc, NTLA] show that its last 5-days average volume of 2.55 million was inferior to 5.06 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 58.56%.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 5.86%, which indicates a significant decrease from 36.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.47 in the past 14 days, which was lower than the 1.04 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.80, while its 200-day Moving Average is $11.33. Now, the first resistance to watch is $9.34. This is followed by the second major resistance level at $9.54. The third major resistance level sits at $9.72. If the price goes on to break the first support level at $8.96, it is likely to go to the next support level at $8.78. The third support level lies at $8.58 if the price breaches the second support level.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
There are currently 115,830K shares outstanding in the company with a market cap of 1.06 billion. Presently, the company’s annual sales total 57,880 K according to its annual income of -519,020 K. Last quarter, the company’s sales amounted to 13,780 K and its income totaled -101,320 K.
